Lymphangiogenesis and colorectal cancer

Ciyou Huang, PhD, Yigang Chen, PhD.

ABSTRACT

Lymphangiogenesis is an important event in the progression of metastasis in colorectal cancer (CRC). The purpose of this article is to assess the role of lymphangiogenesis on CRC. In peritumoral areas of CRC, the lymphatic microvessel density (LMVD) is higher than those in normal colorectal tissues. Moreover, the high LMVD is correlated with DFS and local recurrence in CRC. The VEGF-C/VEGF-D/VEGFR-3 pathway, sonic hedgehog (Shh) signaling pathway and extracellular matrix (ECM) are involved in the regulation of lymphangiogenesis in CRC. Inhibition of the VEGF-C/VEGF-D/VEGFR-3 pathway by specific antibodies has been reported to efficiently inhibit experimental tumor lymphangiogenesis and metastasis in animal experiments. Although lymphangiogenesis has been reported to play an important role in the occurrence of colon cancer and to be associated with prognosis, it remains unclear whether it is a valid therapeutic target molecule. Further study of the potential of targeting this process for anti-lymphatic therapies is worthwhile.

doi: 10.15537/smj.2017.3.16245

From the Department of Endocrinology (Huang), and the Department of General Surgery (Chen), Wuxi Second Hospital, Nanjing Medical University, Jiangsu, China.

Address correspondence and reprint request to: Prof. Yigang Chen, Department of General Surgery, Nanjing Medical University Affiliated Wuxi Second Hospital, Jiangsu, China. E-mail: chyg7676@alumni.sjtu.edu.cn

Colorectal cancer (CRC), a common gastrointestinal malignancy, frequently shows malignant metastatic behavior, which affects different organs, such as the lymph nodes, liver and lungs. In the progress of CRC development, lymphatic metastasis is one of the most important metastatic routes. Clinical findings have suggested that lymphatic vessels are key for metastatic spread because they provide a pathway for tumor cell dissemination. For patients with early stage CRC, which presents without lymph node metastasis, a 5-year survival rate of 80-90% has been reported. However, the 5-year survival rate decreased to 25-60% in patients with advanced stage CRC, which presents with regional lymph node metastasis and involvement of the bowel wall and adjacent structures.

Lymphatic capillaries consist of a single layer of endothelium and a discontinuous basement membrane. One of the main functions of the lymphatic system is to maintain body fluid balance. It is also involved in many physiological and pathological activities, such as immune surveillance, fat absorption and tumor metastasis. However, the research on the relationship between lymphatic vessels and tumor formation is not much, and the results are not consistent. One major obstacle is the absence of effective bio-markers to stain lymphatic endothelium. Recently, novel antibodies, such as D2-40 (podoplanin) and LYVE-1 (lymphatic
endothelial hyaluronan receptor), have emerged which significantly increased the accuracy of the identification of lymphatic vessels. These novel antibodies are effective bio-markers for different types of research associated with lymphatic vessel proliferation.

Lymph node dissection is very important for CRC surgery because lymph node metastasis is an important mode of CRC metastasis. There lymph nodes adjacent to the colon and rectum are abundant, and numerous lymphatic vessels are located longitudinally beneath the colorectal mucosa. At present, the role of lymphangiogenesis in the metastasis of CRC is still controversial. The purpose of this article is to assess the role of lymphangiogenesis on CRC. We review the relationship of lymphangiogenesis with the clinicopathological parameters and survival rate of CRC, and analyze the molecular mechanisms of lymphangiogenesis in the development of CRC.

Relationship between lymphatic microvessel density (LMVD) and clinicopathological parameters of CRC. The detection of LMVD by immunohistochemical method is a reliable and acceptable method. Lymphatic vessels at tumor borders often have large, open lumina, while those centrally located in the tumor have a reticular architecture with numerous tiny and ill-defined lumina. Peritumoral lymphatic vessels are often expanded and functional, while intratumoral lymphatic vessels are typically collapsed and nonfunctional because of the high interstitial pressure within tumors. In the center of colorectal tumors, the lymphatic vessels have no cavities and non-functional streaks, while in the peritumoral areas, the lymphatic vessels have larger lumens with a hollow, oval shape. In the distant normal colorectal tissues, there are fewer lymphatic vessels and they have small lumens (Figure 1). The LMVD was greater at the tumor borders than in the center of the tumor and had large and open lumina in CRC specimens. Therefore, frequently, LMVD values presented by researchers are actually peritumoral LMVD values.

Clinicopathological parameters of CRC are very important for judging disease condition and prognoses and choosing the right treatment strategies. However, the results of studies on the relationships between lymphangiogenesis and clinicopathological parameters of CRC have been inconsistent. Most studies on the relationships between LMVD and clinicopathological parameters of CRC were published from 2006-2011. The results of those studies are presented in Table 1. All of those studies reported that the number of LMVD was higher in the CRC specimens than in normal tissues. For each additional lymphatic vessel, a 1.45-fold increase in the risk of metastasis in CRC was observed.

However, there are inconsistent results regarding the relationships of LMVD with the clinicopathological parameters of CRC, such as tumor stage, degree of differentiation, and distant metastasis. We speculate that these discrepancies might be due to the using different antibodies and lacking standardization for the assessment of LMVD. Currently, 3 antibodies (D2-40, LYVE-1 and CD31) are frequently used for LMVD assessment. However, the specificity of these antibodies was different. For example, D2-40 is sometimes false positive in adenomas and intramuscular carcinomas. Although all studies using the ‘hot spot’ method developed by Weidner et al, different ‘hot spots’ (0.15 mm², 0.24 mm², and 0.74 mm²) were selected. Moreover the LMVD counting was performed by pathologists in some studies and by software in other studies.

Figure 1 - Different shapes of lymphatic vessels in tumor, peritumoral and distant normal tissues: A) center of CRC, lymphatic vessels are collapsed with no cavities and non-functional streaks; B) peritumoral area, lymphatic vessels have a larger size with a hollow, oval shape; C) distant normal tissue, lymphatic vessels are small in number and have small lumens.
Lymphangiogenesis and CRC ... Huang & Chen

Lymphangiogenesis may be an early event in CRC development. Colorectal cancer is a multi-step disease, and approximately 80% CRC develop from adenomas. The adenoma-carcinoma sequence involves accumulation of numerous molecular genetic alterations. Many studies were conducted to determine whether lymphangiogenesis is associated with these genetic alterations. In 2011, Moreia et al performed a retrospective study including 10 colorectal non-neoplastic lesions, 30 colorectal adenomas and 60 sporadic CRC tumors and found that LMVD increased significantly and sequentially from non-neoplastic tissues to adenomas and cancerous tumors. Another study showed that LMVD was significantly higher in adenomas from patients with carcinoma than those in patients without cancer. However, Liang et al reported that LMVD was not higher in colorectal adenomas than in normal colorectal tissues and that LMVD was significantly higher in T1 carcinomas than in Tis carcinomas, colorectal adenomas and normal tissues. Additional studies with larger sample sizes are needed to determine the relationship between lymphangiogenesis and the adenoma-carcinoma sequence.

Table 1 - Studies of lymphangiogenesis with clinicopathological parameters of colorectal cancer (CRC).

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Antibody</th>
<th>Tumor location</th>
<th>Tumor size</th>
<th>Dukes’s/TNM stage</th>
<th>Differentiation</th>
<th>Lymph node metastasis</th>
<th>Distant metastasis</th>
<th>Depth of invasion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saad et al12</td>
<td>2006</td>
<td>D2-40</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Liang et al11*</td>
<td>2006</td>
<td>Podoplanin</td>
<td>NA</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Matsumoto et al17</td>
<td>2006</td>
<td>Podoplanin</td>
<td>No</td>
<td>NA</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Omachi et al15</td>
<td>2007</td>
<td>Podoplanin</td>
<td>No</td>
<td>NA</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kan et al16</td>
<td>2007</td>
<td>Podoplanin</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>Yes</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Duff et al15</td>
<td>2007</td>
<td>LYVE-1</td>
<td>No</td>
<td>NA</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Yan et al8</td>
<td>2008</td>
<td>D2-40</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>NA</td>
<td>No</td>
</tr>
<tr>
<td>Gao et al19</td>
<td>2008</td>
<td>D2-40</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Longatto-Filho et al18</td>
<td>2008</td>
<td>D2-40</td>
<td>NA</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Gao et al19</td>
<td>2009</td>
<td>CD31, D2-40</td>
<td>No</td>
<td>NA</td>
<td>Yes</td>
<td>No</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lin et al9</td>
<td>2010</td>
<td>D2-40, LYVE1</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Holmqvist et al16</td>
<td>2010</td>
<td>D2-40</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Barresi et al20</td>
<td>2011</td>
<td>D2-40</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>NA</td>
</tr>
</tbody>
</table>

*study focused on CRC in early stage, NA - not available, No - not statistically significant, Yes - statistically significant

Lymphangiogenesis with anastomotic leakage of CRC. High LMVD in CRC may relate to anastomotic leakage. Anastomotic leakage is one of the factors that contribute to morbidity, mortality, local recurrence and functional deficits after CRC resection. Despite the enormous progress in surgical techniques for CRC resection, approximately 3-15% of patients experience postoperative anastomotic leakage. A predictive marker of the risk of anastomotic fistula would be very helpful for improving surgical outcomes. In 2011, Chen et al conducted a retrospective study of 750 consecutive patients who underwent anterior resection with restoration of the bowel continuity. They reported that high LMVD in the tumor margins and the distal clearance margin and lower tumor location were independent predictive markers of anastomotic leakage. Their results showed that active lymphangiogenesis and lower tumor localization were independent risk factors for anastomotic leakage. If additional clinical studies obtain similar results, high LMVD may be considered...
Lymphangiogenesis and CRC ... Huang & Chen

a risk factor for anastomotic leakage, and quick frozen section results of LMVD would help surgeons decide whether to create a temporary stoma.

*Relationships of lymphangiogenesis with survival and local recurrence of CRC.* There is great interest in identifying new prognostic markers for CRC patients because they may help improve the clinical or therapeutic management of CRC.38 However, in contrast to microvessel density, the effect of lymphatic microvessel density on survival data remains a subject of intense debate. Many studies suggest that LMVD might be a valuable prognostic factor in colorectal cancer,29-33 while other surveys provide the opposite result.19,34 In 2013, we performed a meta-analysis to examine the relationship between LMVD and the overall survival (OS) and disease-free survival (DFS) of CRC.35 Nine studies including 799 patients who focused on OS or DFS were enrolled. These studies and their results are presented in Table 2. A close relationship was observed between LMVD and DFS (HR 2.29; 95% CI 1.11, 3.48), while no correlation between LMVD and OS was apparent (HR 1.02; 95% CI 0.71, 1.33). Our results suggest that LMVD may be a useful indicator of poor prognosis in CRC patients.

Local recurrence after CRC resection is a severe postoperative complication (with a morbidity of 6-15%) and associated with a poor prognosis. Many efforts have been made to reduce the rate of local recurrence, such as improving surgical techniques and using stapling instruments, but the effects of these changes have not been satisfactory. Therefore, it is very important to identify effective molecular markers to predict and monitor the local recurrence of CRC. Chen et al46 examined LMVD in 352 primary rectal cancer cases and 34 local recurrent specimens. They reported that lymphatic vessel density was one of significant independent predictive factors of local recurrence. Noda et al17 studied lymphangiogenesis in surgical specimens of rectal carcinoma from patients with (n=26) or without (n=74) local recurrence. Their research showed correlation between local recurrence and lymphangiogenesis detected by LMVD and VEGF-C expression. Univariate and multivariate analyses showed that VEGF-C expression was an independent risk factor for the local recurrence of rectal carcinoma. A study by Fania et al28 also showed that high LMVD is an independent predictive factor of disease recurrence in node-negative CRC. The results of these studies suggest that LMVD has an important role in the pathological process of local recurrence of CRC and that markers of lymphangiogenesis may be useful predictors of CRC recurrence.

*Mechanisms of lymphangiogenesis in the processes of CRC.* The invasion and metastasis of cancer cells is a multistep process involving the following successive abnormal changes of lymphatic vessels: cancer cells migrate into nearby lymphatic vessels, transport of cancer cells through the lymphatic systems, escape of cancer cells from the lumina of lymphatic into the distant tissues.58 In this process, lymphatic vessels provide one of the routes for cancer cells metastasis, especially for tumors of the gastrointestinal tract, breast and lung.39 The number and diameter of lymphatic vessels is increased in peritumoral tissues, providing a larger contact area and facilitating tumor cell metastasis. Although the exact mechanism of lymphangiogenesis is unclear, studies have indicated that it may be regulated by the VEGF-C/VEGF-D/VEGFR-3 pathway, sonic hedgehog (Shh) signaling pathway and extracellular matrix (ECM). A simplified schematic is shown in Figure 2.

When considering the possible molecular mechanisms of lymphangiogenesis, major researchers pay attention to the VEGF-C/VEGF-D/VEGFR-3 pathway. This signaling pathway can drive lymphangiogenesis, with ligand-receptor binding stimulating proliferation, survival and migration of lymphatic endothelial cells.40 Prior to the initiation of lymphangiogenesis, VEGF-C can directly disrupt the endothelial lymphatic barrier to promote CRC invasion. In humans, the expression levels of VEGF-D is higher in the heart, lung, skeletal muscle, colon and small intestine than other organs.41 VEGF-C and VEGF-D not only enhance cancer cell metastasis through increasing the number of lymphatic vessels, but also increase vascular leakage and lymph flow, and the resulting increased tumor interstitial fluid pressure helps tumor cells enter the circulatory system.49 Animal studies have provided evidence that overexpression of

**Table 2** - Nine studies investigated the relationship between lymphatic microvessel density (LMVD) and survival time.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Survival data</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jinbo et al81</td>
<td>44</td>
<td>OS</td>
<td>Yes</td>
</tr>
<tr>
<td>Yang et al44</td>
<td>54</td>
<td>OS</td>
<td>No</td>
</tr>
<tr>
<td>Matsumoto et al17</td>
<td>106</td>
<td>OS</td>
<td>Yes</td>
</tr>
<tr>
<td>Fan et al92</td>
<td>80</td>
<td>OS</td>
<td>Yes</td>
</tr>
<tr>
<td>Gao et al39</td>
<td>210</td>
<td>OS</td>
<td>No</td>
</tr>
<tr>
<td>Lin et al9</td>
<td>81</td>
<td>OS</td>
<td>No</td>
</tr>
<tr>
<td>Yan et al132</td>
<td>132</td>
<td>DFS</td>
<td>Yes</td>
</tr>
<tr>
<td>Li et al43</td>
<td>40</td>
<td>DFS</td>
<td>Yes</td>
</tr>
<tr>
<td>Barresi et al49</td>
<td>52</td>
<td>DFS</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Yes - high LMVD is related to colorectal cancer (CRC) patient prognosis, No - LMVD is not related to CRC patient prognosis
VEGF-C or VEGF-D can increase LMVD quantity, diameter and the proliferation rates of tumor-associated lymphatic microvessels. After the VEGF-C/VEGFR-3 axis activated, the formation of lymphatic vessels within and around tumors were increased. In animal tumor models, blocking the VEGF-C/VEGFR-3 signaling pathway not only inhibits the formation of new lymphatic vessels but also reduces metastasis formation.

Recently, the cancer stem cell (CSC) theory has emerged as an attractive hypothesis for the processes of tumor development and progression. Cancer stem cells participate in lymphangiogenesis directly and indirectly. The Shh signaling pathway plays a critical role in stem cell maintenance and in specifying patterns of cell growth and differentiation. The Shh signaling pathway is correlated with lymphangiogenesis in many tumor types. Young et al reported that Shh signaling promotes metastasis and lymphangiogenesis via activation of Akt, the EMT (epithelial to mesenchymal transition), and the MMP-9 pathway in gastric cancer. A study by Bailey et al showed that Shh signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. However, few studies focused on the relationship between the CSC and Shh signaling pathway with lymphangiogenesis in CRC. We hypothesize that Shh signaling pathway has a role in lymphangiogenesis in CRC and it is worth studying in the future. The ECM plays an important role in the generation and growth of new lymphatic microvessels. Extracellular matrix-lymphatic vessels interactions as well as biophysical characteristics of the stroma have consequences for tumor formation, growth and metastasis. In the ECM, anchoring filaments adhere to the outside of the lymphatic endothelial cell and connect to elastic fibers. These anchoring filaments allow for fluid and cells to initially enter the lymphatic system. There are many ligands in the ECM, including...
To block VEGFR-3, has been investigated for use in combination with FOLFOX-4 in phase III clinical trials for metastatic CRC, but the current results are negative.56 In addition to antibodies that VEGF inhibit, new therapeutic approaches are being tested in experimental clinical studies. AEE788, a dual-receptor tyrosine kinase inhibitor of EGFR and VEGFR-2, is currently being investigated in clinical trials. In a colon cancer orthotopic animal model, AEE788 decreased the number of peritumoral lymphatic vessels and the incidence of lymph node metastasis by decreasing the migration, proliferation and survival of lymphatic endothelial cells.57 Karaday et al58 showed that iNOS-mediated NO formation plays an important role in tumor lymphangiogenesis and the development of lymphatic metastases. Inhibition of the NO pathway may be an alternative treatment for gastric carcinoma. The above studies suggest that lymphangiogenesis and anti-lymphangiogenesis are complex processes that involve several pathways. When one signaling pathway is blocked, others may compensate for its absence. Therefore, future anti-lymphatic treatment strategies may be complex involving inhibitors of multiple pathways.6

Summary and perspectives. Clinicopathological findings have suggested that lymphangiogenesis may be an early event in CRC development. Lymphatic microvessel density is correlated with DFS and local recurrence of CRC and, thus, may be an indicator of poor prognosis in CRC patients. However, there are no clear relationships between LMVD and some important clinicopathological parameters of CRC, such as tumor location, degree of differentiation, tumor stage, invasive depth and distant metastasis. In future clinical studies with larger sample sizes, uniform methods for the detection and counting of LMVD are required.

Inhibition of the VEGF-C/VEGF-D/VEGFR-3 pathway by specific antibodies, soluble receptor constructs and small molecule kinase inhibitors has been reported to efficiently inhibit experimental tumor lymphangiogenesis and metastasis.54 Sorafenib, a small molecule inhibitor that targets the RAF/MEK/ERK pathway, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor (PDGFR-b), has been approved by the FDA for the treatment of advanced renal cell carcinoma.55 Vatalanib, a small molecule inhibitor that blocks VEGF-3, has been investigated for use in combination with FOLFOX-4 in phase III clinical trials for metastatic CRC, but the current results are negative.56

Many strategies have been used to prevent lymphatic metastasis, and some studies have shown potential approaches for blocking the growth of lymphatic vessels to prevent tumor metastasis.52 Therapy. Many strategies have been used to prevent lymphatic metastasis, and some studies have shown potential approaches for blocking the growth of lymphatic vessels to prevent tumor metastasis.52 Inhibition of the VEGF-C/VEGF-D/VEGFR-3 pathway by specific antibodies, soluble receptor constructs and small molecule kinase inhibitors has been reported to efficiently inhibit experimental tumor lymphangiogenesis and metastasis.54 Sorafenib, a small molecule inhibitor that targets the RAF/MEK/ERK pathway, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor (PDGFR-b), has been approved by the FDA for the treatment of advanced renal cell carcinoma.55 Vatalanib, a small molecule inhibitor that blocks VEGF-3, has been investigated for use in combination with FOLFOX-4 in phase III clinical trials for metastatic CRC, but the current results are negative.56 In addition to antibodies that VEGF inhibit, new therapeutic approaches are being tested in experimental clinical studies. AEE788, a dual-receptor tyrosine kinase inhibitor of EGFR and VEGFR-2, is currently being investigated in clinical trials. In a colon cancer orthotopic animal model, AEE788 decreased the number of peritumoral lymphatic vessels and the incidence of lymph node metastasis by decreasing the migration, proliferation and survival of lymphatic endothelial cells.57 Karaday et al58 showed that iNOS-mediated NO formation plays an important role in tumor lymphangiogenesis and the development of lymphatic metastases. Inhibition of the NO pathway may be an alternative treatment for gastric carcinoma. The above studies suggest that lymphangiogenesis and anti-lymphangiogenesis are complex processes that involve several pathways. When one signaling pathway is blocked, others may compensate for its absence. Therefore, future anti-lymphatic treatment strategies may be complex involving inhibitors of multiple pathways.6

Summary and perspectives. Clinicopathological findings have suggested that lymphangiogenesis may be an early event in CRC development. Lymphatic microvessel density is correlated with DFS and local recurrence of CRC and, thus, may be an indicator of

References


